title: [Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
abstract: Actually gemcitabine is a main drug in the treatment of non small cell lung cancer (NSCLC). The doublet gemcitabine and cisplatin is a standard treatment, widely used in the world. The review of the literature, and specially several recent randomised phase III trial in stage IV NSCLC demonstrates the reproducibility of the results, and a manageable toxicity which allows its use in preoperative setting in stages I, II and resectable III. The carboplatin-gemcitabine doublet is under investigation.
authors.affiliation: Hospices civils de Lyon, Centre hospitalier Lyon-Sud, 69495 Pierre-Bénite. pierre-jean.souquet@chu-lyon.fr
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Souquet
authors.forename: Laurence
authors.initials: L
authors.lastname: Gerinière
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077143:Docetaxel; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000601:surgery*; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011013:Pneumonectomy; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D015203:Reproducibility of Results; D043823:Taxoids; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D014747:Vinblastine; D005047:Etoposide; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine